Trials / Completed
CompletedNCT00722358
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-650032 | Capsule, Oral, Q12h, 3/5 days Panel 1: 200 mg Panel 2: 400 mg Panel 3: 600 mg |
| DRUG | Placebo | Capsule, Oral, Q 12h, 3/5 days Panel 1: matching placebo Panel 2: matching placebo Panel 3: matching placebo |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-07-25
- Last updated
- 2011-06-27
Locations
5 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00722358. Inclusion in this directory is not an endorsement.